ProShares UltraShort NASDAQ Biotechnology
14 hedge funds and large institutions have $7.39M invested in ProShares UltraShort NASDAQ Biotechnology in 2016 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 2 closing their positions.
185% more call options, than puts
Call options by funds: $21.9M | Put options by funds: $7.67M
0% more funds holding
Funds holding: 14 → 14 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
76% less capital invested
Capital invested by funds: $30.8M → $7.39M (-$23.4M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HighTower Advisors
Chicago,
Illinois
|
+$783K |
| 2 |
CT
CMT Trading
Chicago,
Illinois
|
+$366K |
| 3 |
Jane Street
New York
|
+$103K |
| 4 |
CG
Cutler Group
San Francisco,
California
|
+$76.2K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$24.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
-$19.2M |
| 2 |
VF
Virtu Financial
New York
|
-$1.48M |
| 3 |
FAM
Fred Alger Management
New York
|
-$1.43M |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$882K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$742K |
BIS Hedge Fund Activity: Q2 2016 in Review
14 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q2 2016, worth a combined $7.39M — down 76% from $30.8M a quarter earlier.
Fund positioning in BIS was balanced in Q2 2016: 2 funds opened new positions, 2 closed out, 4 added to existing stakes and 6 trimmed.
The largest buyer was HighTower Advisors, adding an estimated $783K. The largest seller was Ardsley Advisory Partners, exiting entirely with an estimated $19.2M sold.
- 14 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q2 2016, unchanged from Q1 2016.
- Funds reported $7.39M of ProShares UltraShort NASDAQ Biotechnology stock for Q2 2016, down 76% quarter-over-quarter.
- 2 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q2 2016 and 2 closed out, a net change of 0 holders.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q2 2016 was HighTower Advisors, an estimated $783K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q2 2016 was Ardsley Advisory Partners, an estimated $19.2M sold.
Based on aggregated 13F filings for Q2 2016.